Quality, compliance, and validation support for drug and biologics manufacturers operating under 21 CFR Parts 210/211 and cGMP requirements, where FDA inspection can come at any time.
IQ/OQ/PQ documentation, audit trail integrity, and change-controlled operations across quality systems, laboratory systems, and validated ERP platforms.
For biologics and biosimilars, validated systems underpin batch record integrity, manufacturing execution, and quality event management.
Biotech organizations moving to commercial production face more complex quality and validation requirements as processes and regulatory oversight intensify.
Documentation, validated systems, and electronic records ready before the inspection window.
A pharmaceutical organization mid-ERP upgrade or revalidation without sufficient internal headcount to manage IQ/OQ/PQ and change control requirements.
A biotech preparing for its first FDA pre-approval inspection needs contract compliance and CSV support, including mock inspections, documentation review, and validated systems and electronic records that meet Part 11 and Annex 11 requirements before the inspection window.
A pharmaceutical organization under FDA warning letter needs a compliance lead, a quality systems consultant, and a CSV specialist to support remediation commitments within the agency's required timeline.
Tell us about your organization, regulatory environment, and need. We will scope the engagement against your specific GxP context.